Page 1

Heidelberg PHARMA Focused Cancer Therapies • HDP - 101 : application to initiate clinical trial green - lighted by the FDA in February 2021 ; clinical trial centers prepare to receive their first patient ; clinical trial application also submitted to the Paul Ehrlich Institute in Germany ● New preclinical data on the immunomodulatory potential of Antibody Targeted Amanitin Conjugates presented at the AACR 2021 Annual Meeting Shareholder loan and financing commitment for up to € 30 million obtained from main shareholder dievini • Successful corporate action for € 20 million implemented Operating result in line with planning ; progress made in development program leads to increase in research and development costs شای نماز HALF - YEARLY FINANCIAL REPORT 2021